Securities code: Chison Medical Technologies Co.Ltd(688358) securities abbreviation: Chison Medical Technologies Co.Ltd(688358) Announcement No.: 2022001 Chison Medical Technologies Co.Ltd(688358)
Announcement of 2021 annual performance express
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the 2021 annual report of Chison Medical Technologies Co.Ltd(688358) (hereinafter referred to as “the company”), which draws the attention of investors to investment risks.
1、 Main financial data and indicators in 2021
Unit: RMB 10000
Increase / decrease range of the project in the same period of last year in the reporting period (%)
Total operating income 40670173330927 22.10
Operating profit 13469861087833 23.82
Total profit 13381071115116 20.00
Owner of parent company
1198212 net profit of 996361 20.26
Attributable to the owner of the parent company
855810908826 -5.83 net profit after deducting non recurring profit and loss
Basic earnings per share (yuan) 1.50 1.25 20.00
The weighted average return on net assets (%) was 9.84 and 8.54, an increase of 1.30 percentage points
Increase / decrease range at the end of the reporting period (%)
Total assets 1409522413496040 4.44
Owner’s equity attributable to the parent company 1253034711929051 5.04
Share capital (10000 shares) 8000-
Attributable to the owner of the parent company
15.66 14.91 5.03 net assets per share (yuan)
Note: 1 The beginning amount of this report is the same as the end amount of the previous year legally disclosed.
2. The above financial data and indicators are filled in with the data in the consolidated statements, but have not been audited. The final results are subject to the company’s 2021 annual report.
2、 Description of operating performance and financial status
(I) operation and financial status during the reporting period
During the reporting period, the company achieved an operating income of 4067017 million yuan, a year-on-year increase of 22.10%; The net profit attributable to the owners of the parent company was 1198212 million yuan, a year-on-year increase of 20.26%; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 85.581 million yuan, a year-on-year decrease of 5.83%; The basic earnings per share was 1.50 yuan, a year-on-year increase of 20.00%.
At the end of the reporting period, the company was in good financial condition, with total assets of 1409522400 yuan, a year-on-year increase of 4.44%; The owner’s equity attributable to the parent company was 1253034700 yuan, a year-on-year increase of 5.04%; The net assets per share attributable to the owners of the parent company was 15.66 yuan, a year-on-year increase of 5.03%.
(II) main factors affecting operating performance
During the reporting period, the company continuously increased the research and development of new products, made pre research reserves for medium and long-term new technologies, continued to maintain a high proportion of R & D investment, and the annual R & D expenses increased by 29.82% year-on-year; While increasing R & D investment, the company vigorously explored markets outside China, accelerated the construction of marketing system and network layout, and the annual sales expenses increased by 31.11% year-on-year. Both R & D expenses and sales expenses increased significantly, resulting in a slightly lower growth rate of net profit than that of operating revenue. 3、 Risk tips
The main financial data of 2021 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data shall be subject to the company’s 2021 annual report. Please pay attention to the investment risks.
It is hereby announced.
Chison Medical Technologies Co.Ltd(688358) board of directors February 28, 2022
